John M. Holliman, III, 53, became Executive Chairman and Principal Executive Officer of the Company on April 5, 2006 and has served as a director of the Company since September 1987 and as Chairman of the Board of Directors since August 1997. Since February 1993 he has been a general partner of entities, which are the general partners of Valley Ventures, LP (formerly known as Arizona Growth Partners, LP), Valley Ventures II, LP and Valley Ventures III, LP, all of which are venture capital funds that invest principally in life science companies. (Close)

Randolph C. Steer, MD, Ph.D., 57, became President of the Company on April 5, 2006. Dr. Steer has been an independent pharmaceutical, biotechnology and medical devices consultant since 1989, and has provided consulting services to OrthoLogic since 2002. He has a broad scientific, medical and business background, including extensive experience in pre-clinical, clinical and regulatory affairs, having held key management positions in leading corporations and having served as an advisor to many companies in the United States and abroad. Dr. Steer has also advised numerous venture capital firms, investment banks and independent investors on the commercial development of drugs, biologics, diagnostics and medical devices. He has served as Associate Director of Medical Affairs at Marion Laboratories; Medical Director at Ciba Consumer Pharmaceuticals (Ciba-Geigy Corporation); Vice President, Senior Vice President and Member of the Executive Committee at Physicians World Communications Group; Chairman, President and Chief Executive Officer of Advanced Therapeutics Communications International, a global drug regulatory group, and Chairman and Chief Executive Officer of Vicus.com, Inc. He is a member of the Board of Directors of Techne Corporation and BioCryst Pharmaceuticals. Dr. Steer received his MD degree from the Mayo Medical School and his Ph.D. from the University of Minnesota, where he also completed a residency and subspecialty fellowship in clinical and chemical pathology. He is a Fellow of the American College of Clinical Pharmacology. (Close)

Les M. Taeger, 56, joined OrthoLogic as Senior Vice President and Chief Financial Officer on January 16, 2006. Mr. Taeger most recently served as Chief Financial Officer of CardioTech International, Inc. (“CardioTech”). CardioTech is a publicly-traded, medical device company that develops, manufactures and sells advanced products for the treatment of cardiovascular disease. From September, 2000 to February, 2004, when Mr. Taeger became Chief Financial Officer of CardioTech, Mr. Taeger served as Chief Financial Officer of Gish Biomedical, Inc. (“Gish”). Gish, now a subsidiary of CardioTech pursuant to a merger transaction involving the companies in April, 2003, specializes in the manufacture and sale of products used in open-heart surgery, vascular access and orthopedic surgery. Prior to his employment with CardioTech and Gish, Mr. Taeger was employed for over five years as Chief Financial Officer of Cartwright Electronics, Inc., a division of Meggitt, PLC. Mr. Taeger is a Certified Public Accountant, with a Bachelor degree in accounting. (Close)

Dana B. Shinbaum, 44, joined OrthoLogic as Vice President of Business Development in October 2005. Previously he served as Vice President, Product Planning and Market Analytics at Savient Pharmaceuticals, Inc., and has over seventeen years of experience in the pharmaceutical/biotechnology industry. While at Savient his responsibilities included creating and developing new business opportunities, leading global project teams and managing product launches. He played key strategic planning roles in Savient’s acquisition of Rosemont Pharmaceuticals Ltd. and the divestiture of Bio-Technology General Ltd., Savient’s global biologics business. Prior to joining Savient, Mr. Shinbaum was at Wyeth-Ayerst Laboratories, where he served in a variety of market planning and marketing roles, including Product Manager for the PREMARIN® franchise. Mr. Shinbaum received a Master of Business Administration, summa cum laude, from Drexel University in Philadelphia and a Bachelor of Arts degree from Lafayette College in Easton, Pennsylvania. (Close)

Fredric J. Feldman, Ph.D., 66, has been the President of FJF Associates, a consultant to health care venture capital and emerging companies, since February 1992. From September 1995 to June 1996, he was the Chief Executive Officer of Biex, Inc., a women’s healthcare company. He served as Chief Executive Officer of Oncogenetics, Inc., a cancer genetics reference laboratory from 1992 to 1995. Between 1988 and 1992, Dr. Feldman was the President and Chief Executive Officer of Microgenics Corporation, a medical diagnostics company. He has been a director of a number of public and private companies involved in the healthcare industry. (Close)

John M. Holliman, III, 53, became Executive Chairman and Principal Executive Officer of the Company on April 5, 2006 and has served as a director of the Company since September 1987 and as Chairman of the Board of Directors since August 1997. Since February 1993 he has been a general partner of entities, which are the general partners of Valley Ventures, LP (formerly known as Arizona Growth Partners, LP), Valley Ventures II, LP and Valley Ventures III, LP, all of which are venture capital funds that invest principally in life science companies. (Close)

Elwood D. Howse, Jr., 67, has served as a director of the Company since September 1987. In 1982, Mr. Howse founded Cable, Howse and Ragen, investment banking and stock brokerage firm, now owned by Wells Fargo and known as Ragen MacKenzie. In 1977, Mr. Howse co-founded Cable & Howse Ventures, an early stage venture capital firm focused on technology. In 1976, he served as Vice President, Corporate Finance, for Foster & Marshall, a northwest stock brokerage firm. In 1974 he was the Chief Financial Officer of Seattle Stevedore Company and the Miller Produce Company. Mr. Howse has served as a corporate director and advisor to various public, private and non-profit enterprises. He served on the board of the National Venture Capital Association and is past President of the Stanford Business School Alumni Association. He currently serves on the boards of directors of BSQUARE Corporation (BSQR), Formotus, Inc., Perlego Systems Inc., PowerTech Group, Inc., and not-for-profits, Junior Achievement Worldwide and Junior Achievement of Washington. (Close)

Dr. Wardell, 68, was appointed by the OrthoLogic Board of Directors on February 11, 2006, to fill a vacancy (Class III) on the Board. He owns and operates the consulting firm Wardell Associates International LLC in Princeton, NJ, where he specializes in drug development, regulatory approval, and safety for a range of pharmaceutical and biotechnology companies. Dr. Wardell has published over one hundred scientific papers and four books, and has testified as an expert in drug development during several Congressional hearings. Dr. Wardell has 22 years of experience in the healthcare industry, holding leadership positions as President, Protein Engineering Corporation (now DYAX); Senior Vice President of Drug Development, Parke-Davis; Vice President and Medical Director, Boehringer Ingelheim Pharmaceuticals; Senior Scientific Officer, Covance; and Executive Director of the Covance Institute for Drug Development Sciences. During his tenure at these companies, Dr. Wardell was responsible for 11 approved New Drug Applications. He previously served as an associate professor of Pharmacology, Toxicology and Medicine, attending on the Clinical Pharmacology consultation service of Strong Memorial Hospital at the University of Rochester Medical Center, where he co-founded and directed the University’s Center for the Study of Drug Development. Dr. Wardell earned his MA, PhD in pharmacology, and MD at the University of Oxford (UK), and was a Merck International Fellow in Clinical Pharmacology and Medicine under Dr. Louis Lasagna at the University of Rochester / Strong Memorial Hospital. He currently serves on the Board of Directors of PhytoCeutica, Inc., the Scientific Advisory Board of Eleos, Inc., and the Board of the American Board of Clinical Pharmacology. (Close)

Dr. White, 70, became a director of the Company in July 1993. He is the former Master of the Oliver Wendell Holmes Society and currently the Ellen and Melvin Gordon Professor of Medical Education and Professor of Orthopedic Surgery at the Harvard Medical School and the Harvard-MIT Division of Health Sciences and Technology since July 1978; and Orthopedic Surgeon-in-Chief, Emeritus, at the Beth Israel Deaconess Medical Center in Boston since 1990. From 1992 to 1994, he served as the Chief of Spine Surgery at Beth Israel and is Director of the Daniel E. Hogan Spine Fellowship Program. He is a graduate of Brown University, the Stanford University Medical School, holds a Ph.D. from the Karolinska Institute in Stockholm, and graduated from the Advanced Management Program at the Harvard Business School. Dr. White is a recipient of the Bronze Star, which he earned while stationed as a Captain in the U.S. Army Medical Corps in Vietnam. Dr. White is currently a director of Zimmer Holdings, Inc., a publicly held designer, marketer and manufacturer of orthopedic products. (Close)

Charles A. Dinarello, M.D. is a Professor of Medicine at the University of Colorado School of Medicine in Denver. Until 1996, he was Professor of Medicine and Pediatrics at Tufts University School of Medicine and a staff physician at the New England Medical Center Hospital in Boston. Dr. Dinarello received his medical degree from Yale University and his clinical training at the Massachusetts General Hospital. From 1971 to 1974 he was a clinical associate and from 1975 to 1977 a senior investigator at the National Institutes of Health in Bethesda. Dr. Dinarello has published over 500 original research articles on cytokines, particularly Interleukin-1 and Tumor Necrosis Factor. The Institute for Scientific Information listed him as the world's fourth most cited scientist (all science) for the 20 years (1983-2003). He was elected to the United States National Academy of Sciences in 1998 and is currently a member of the editorial board of Proceedings of the National Academy of Sciences. Dr. Dinarello has trained over 40 investigators, many of whom are recognized experts in their fields. He has served on the Board of Scientific Advisors of the National Institutes of Allergy and Infectious Diseases and is currently on the Board of Advisors of the Alliance for Lupus Research. He was Vice President of the American Society of Clinical Investigation (1989-1990) and President of the International Cytokine Society (1995-1996). The recipient of multiple prestigious awards for his contributions to the field of infectious diseases and cytokines, he received Germany's Ernst Jung Prize in Medicine in 1993. He donated the entire prize money ($125,000) to universities and research institutes in the United States and Israel, and established the Sheldon M. Wolff Professorship at Tufts University to honor his late mentor. In 1996, he received the Ludwig Heilmeyer Gold Medal of the Society for Internal Medicine (Germany, Austria, and Switzerland) for his contributions to progress in internal medicine. He is also the recipient of the Chirone International Prize from the Italian Academy of Medicine. Dr. Dinarello has received honorary doctorates from the University of Marseille (France), Weizmann Institute of Science (Israel) and University of Frankfurt (Germany). In 2006, he received the Sheikh Hamdan Bin Rashid Al-Maktoum Award for Medical Research Excellence (United Arab Emirates). (Close)

Michael E. Mendelsohn, M.D., F.A.C.C., is the Executive Director of the Molecular Cardiology Research Institute at New England Medical Center and the first recipient of the Elisa Kent Mendelsohn Professorship of Molecular Cardiology and Medicine at Tufts University School of Medicine. Dr. Mendelsohn is also the Vice-Chairman for Scientific Affairs of the Department of Medicine and Chairman of the Research Executive Committee for Tufts-New England Medical Center. Dr. Mendelsohn is an international leader in the study of molecular vascular biology. As a physician-scientist, Dr. Mendelsohn has focused on signal transduction pathways regulating vascular tone and function. His laboratory has contributed importantly to deciphering the mechanisms of action of endogenous vascular protective molecules, including estrogen/estrogen receptors and nitric oxide/cyclic GMP signaling pathways in cardiovascular physiology and disease. Dr. Mendelsohn joined the Cardiology Division at Tufts-New England Medical Center in 1993 as the Director of the Molecular Cardiology Research Center and an Associate Professor of Medicine, Tufts University School of Medicine. Dr. Mendelsohn received his B.A. magna cum laude from Amherst College in 1978 and his M.D. from Harvard Medical School in 1982, followed by residency in Internal Medicine and fellowship in Cardiovascular Medicine at Brigham and Women's Hospital. He was a member of the staff of the BWH Cardiology Division from 1988-1993 and an Assistant Professor of Medicine at Harvard Medical School. Dr. Mendelsohn's laboratory is funded principally by the National Institutes of Health. He has been the Principal Investigator on numerous NIH awards, including a Specialized Center of Research in Ischemic Heart Disease and a Program Project Grant studying molecular mechanisms of vascular relaxation. He is the recipient of an Established Investigatorship from the American Heart Association, the Sir William Osler Young Investigator Award of the Interurban Clinical Club, and both the Distinguished Faculty Award and the Milton O. and Natalie V. Zucker Faculty Award for Outstanding Research from Tufts University School of Medicine. Dr. Mendelsohn was an Invited Speaker at the Nobel Symposium, "Estrogen and Women's Health" in Karlskoga, Sweden in 1999 and the Chairman of the Experimental Cardiovascular Sciences Study Section of the NIH from 2000-2002, and is an Invited Speaker to the 2008 Nobel Conference, "Recent Advances in Understanding Estrogen Signaling" in Stockholm, Sweden. Dr. Mendelsohn's awards also include election to the American Society of Clinical Investigation (ASCI), the Association of University Cardiologists (AUC) and the Association of American Physicians (AAP). (Close)